EKF Diagnostics, the maker of point-of-care testing equipment and enzymes for the life sciences industry, has told investors it remains on track for its full-year expectations after a first half of stable Revenue and higher margins. Interim results for the six months to 30 June 2026, published in mid-September 2026, showed revenue of £25.0m, adjusted EBITDA up 2.4% to £5.9m and a cash balance of £16.0m, according to summaries of the announcement.

What the company does

EKF operates in two broad areas. Its Point-of-Care Business makes analysers and tests used in clinics and hospitals, including beta-hydroxybutyrate (β-HB) measurement products. Its Life Sciences business produces enzymes and other materials through fermentation, including at its Facility in south Wales, and the group also offers contract manufacturing.

Latest developments

A first-half trading update in late July 2026 gave the first indication of the period's performance, putting revenue at about £25.0m compared with £25.2m a year earlier. It reported Life Sciences revenue up about 20%, β-HB revenues up 4% and good performance in contract manufacturing. The update also referred to a share buyback, with £0.9m allocated.

The interim results confirmed that picture, describing Life Sciences as robust and Point-of-Care revenues as recovering. The company said it had a strong committed order book for the second half and expected full-year growth in line with consensus. The July update cited consensus forecasts for 2026 of £54.7m revenue and £13.6m adjusted EBITDA.

The figures build on the previous year. In July 2025, the company reported net cash of £14.4m at 30 June 2025 and said Demand for enzymes was driving growth in Life Sciences. Chief executive Mike Salter said then that the business was focused on disciplined cost control and organic growth, and the group was investing in fermentation capacity at its south Wales site to meet that demand.

Financial and Dividend picture

Gross profit was £13.3m in the half, giving a gross Margin of about 53%, up from roughly 50% a year earlier. Profit before tax was reported at £3.4m. Cash stood at £16.0m at 30 June 2026, and the July update said the group had no bank borrowings. Summaries of the interim announcement reviewed for this article did not include details of an interim dividend, so readers should consult the full statement. The company has been returning cash through its share buyback programme.

Sector and index context

EKF is part of the healthcare segment of the FTSE AIM All Share Index. Diagnostics companies have had to adjust to the end of pandemic-era testing demand, with attention shifting to routine testing, chronic disease management and Supply to pharmaceutical and biotechnology customers. Demand for enzymes produced through fermentation has been one of the stronger areas for the group.

Key risks

Point-of-Care sales depend on purchasing by healthcare systems and distributors in many countries, which can be lumpy. The second-half weighting implied by full-year consensus means delivery of the committed order book is important. Investment in Manufacturing capacity carries execution risk, and currency movements can affect overseas earnings. Several figures in this article come from automated summaries of company announcements, and the original statements remain the definitive source.

What to watch next

Investors will watch for a trading update around the year end on whether second-half orders have converted into revenue, progress on the share buyback and further growth in Life Sciences. Full-year results for 2026 are expected in 2027.